Toronto Dominion Bank Fennec Pharmaceuticals Inc. Transaction History

Toronto Dominion Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$8.82 - $11.12 $520 - $656	-59 Reduced 70.24%	25 $0
Q4 2023 Feb 13, 2024	BUY	$6.48 - $11.61 $123 - $220	19 Added 29.23%	84 $0
Q3 2023 Feb 14, 2024	SELL	$7.15 - $8.94 $57 - $71	-8 Reduced 10.96%	65 $0
Q3 2023 Nov 14, 2023	SELL	$7.15 - $8.94 $57 - $71	-8 Reduced 10.96%	65 $0
Q2 2023 Feb 14, 2024	SELL	$7.27 - $9.82 $79 - $108	-11 Reduced 13.1%	73 $1,000
Q2 2023 Aug 10, 2023	SELL	$7.27 - $9.82 $184,127 - $248,711	-25,327 Reduced 99.71%	73 $1,000
Q1 2023 May 11, 2023	BUY	$7.38 - $10.35 $187,452 - $262,890	25,400 New	25,400 $204,000
Q2 2022 Aug 11, 2022	SELL	$5.17 - $6.33 $51 - $63	-10 Reduced 14.08%	61 $0
Q1 2022 May 09, 2022	BUY	$4.29 - $6.08 $72 - $103	17 Added 31.48%	71 $0
Q4 2021 Feb 04, 2022	BUY	$3.89 - $10.01 $120 - $310	31 Added 134.78%	54 $0
Q3 2021 Nov 08, 2021	SELL	$6.51 - $9.62 $208 - $307	-32 Reduced 58.18%	23 $0
Q2 2021 Aug 13, 2021	BUY	$5.96 - $7.85 $327 - $431	55 New	55 $0

14.8M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $171M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.